These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 25850293)

  • 1. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips].
    Fedorova OE; Liubchenko LN; Paiadini IuG; Kazubskaia TP; Amosenko FA; Gar'kavtseva RF; Zasedatelev AS; Nasedkina TV
    Mol Biol (Mosk); 2007; 41(1):37-42. PubMed ID: 17380889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
    Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.
    Grzybowska E; Siemińska M; Zientek H; Kalinowska E; Michalska J; Utracka-Hutka B; Rogozińska-Szczepka J; Kaźmierczak-Maciejewska M
    Acta Biochim Pol; 2002; 49(2):351-6. PubMed ID: 12362976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.
    Suspitsin EN; Sherina NY; Ponomariova DN; Sokolenko AP; Iyevleva AG; Gorodnova TV; Zaitseva OA; Yatsuk OS; Togo AV; Tkachenko NN; Shiyanov GA; Lobeiko OS; Krylova NY; Matsko DE; Maximov SY; Urmancheyeva AF; Porhanova NV; Imyanitov EN
    Hered Cancer Clin Pract; 2009 Feb; 7(1):5. PubMed ID: 19338682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Analysis of Multiple Primary Malignant Tumors in Women with Breast and Ovarian Cancer.
    Savkova A; Gulyaeva L; Gerasimov A; Krasil'nikov S
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT.
    Rybchenko LA; Poluben LO; Bychkova GM; Stephanovych GV; Klymenko SV
    Probl Radiac Med Radiobiol; 2019 Dec; 24():455-464. PubMed ID: 31841487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.
    Sokolenko AP; Rozanov ME; Mitiushkina NV; Sherina NY; Iyevleva AG; Chekmariova EV; Buslov KG; Shilov ES; Togo AV; Bit-Sava EM; Voskresenskiy DA; Chagunava OL; Devilee P; Cornelisse C; Semiglazov VF; Imyanitov EN
    Fam Cancer; 2007; 6(3):281-6. PubMed ID: 17333477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
    Skasko E; Kluska A; Niwińska A; Kwiatkowska E; Bałabas A; Piatkowska M; Dabrowska M; Nowakowska D; Pieńkowski T
    Onkologie; 2009 Apr; 32(4):182-8. PubMed ID: 19372713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 mutations in a South American population.
    Jara L; Ampuero S; Santibáñez E; Seccia L; Rodríguez J; Bustamante M; Martínez V; Catenaccio A; Lay-Son G; Blanco R; Reyes JM
    Cancer Genet Cytogenet; 2006 Apr; 166(1):36-45. PubMed ID: 16616110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
    Krivokuca A; Dobricic J; Brankovic-Magic M
    J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.